Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit
08:16am, Sunday, 18'th Jan 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired secur
NEW YORK, Jan. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, I
VTGN Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vistagen Therapeutics, Inc.
11:43pm, Friday, 16'th Jan 2026
SAN DIEGO, Jan. 16, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
09:00pm, Friday, 16'th Jan 2026
NEW YORK, Jan. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock betwee
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
03:42pm, Friday, 16'th Jan 2026
LOS ANGELES--(BUSINESS WIRE)---- $VTGN--VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (VTGN)
01:17pm, Friday, 16'th Jan 2026
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of C
ATLANTA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN). The lawsuit alleg
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
07:57pm, Thursday, 15'th Jan 2026
SAN DIEGO--(BUSINESS WIRE)---- $VTGN #Health--Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NA
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Vistagen T
Contrasting Fulcrum Therapeutics (NASDAQ:FULC) & VistaGen Therapeutics (NASDAQ:VTGN)
01:44am, Wednesday, 07'th Jan 2026
Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) and VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare
Traders Purchase Large Volume of Put Options on VistaGen Therapeutics (NASDAQ:VTGN)
02:07am, Saturday, 27'th Dec 2025
VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) was the target of unusually large options trading activity on Friday. Traders purchased 2,482 put options on the company. This is an increa
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
12:42pm, Wednesday, 17'th Dec 2025
Vistagen Inc. (NASDAQ: VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci
